Φορτώνει......
Prognosis Varies by Intrinsic Tumor Subtype in Patients Treated with Ribociclib
According to a new biomarker analysis of the MONALEESA trials, intrinsic tumor subtype is an important predictor of clinical outcomes in patients with HR‐positive/HER2‐negative breast cancer treated with ribociclib and endocrine therapy.
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Oncologist |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley & Sons, Inc.
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7869330/ https://ncbi.nlm.nih.gov/pubmed/33399246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13660 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|